Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

New Clues to the Challenge of Knee Arthrofibrosis: From Molecules to Therapies

Thaler R., Payne AN., Berry DJ., Abdel MP.

Narrative Review on Osteoarthritis, Chronic Inflammation, published in J Am Acad Orthop Surg (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Am Acad Orthop Surg (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41144907
PMCID
PMC13154343
DOI
10.5435/jaaos-d-25-00860

Abstract (original English)

Knee arthrofibrosis (AF) is a debilitating complication after total knee arthroplasty. AF is characterized by formation of fibrotic adhesions, loss of joint mobility, and pain. With osteoarthritis prevalence and associated total knee arthroplasties projected to rise sharply, AF is becoming increasingly prevalent, yet its pathogenesis remains poorly understood and no effective treatments exist. Like other fibrotic diseases, knee AF is a multifactorial disease that exhibits TGFβ1-driven myofibroblast transformation and excessive collagen deposition. However, knee AF also displays unique features, including rapid disease development and the establishment of a highly fibrotic mass rather than fibrotic tissue infiltration. Our integrative research approach uses human patient fibroblasts, multiomics profiling, and in vivo animal models to dissect disease mechanisms and identify therapeutic targets. Our work suggests altered adipogenic cell differentiation in the knee and epigenetic pathways controlling myofibroblastogenesis to be involved in AF development. Anti-inflammatory interventions with ketotifen and celecoxib reduce knee AF in vivo, indicating a contributory role of inflammation as well. Together, our novel findings elucidate causal and mechanistic drivers of AF and define this disease as an adipose-depleted fibrotic disorder driven by aberrant differentiation and epigenetic

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Knee JointFibroblastsAnimalsHumansJoint DiseasesFibrosisPostoperative ComplicationsArthroplasty, Replacement, KneeCell DifferentiationEpigenesis, Genetic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research